Fig. 3From: Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancerDistribution of treatments and its association with clinical outcomes measured by PFS and OS. A Distribution of treatments in patients carrying alterations with different actionability levels. B PFS and OS in patients carrying potentially actionable alterations who were treated with a matched therapy and a nonmatched therapyBack to article page